verified SJR 0,57 · Q2 • database Scopus / SJR & Web of Science indexed

United Kingdom · Wiley-Blackwell Publishing L...

workspace_premium Q2 — Medicine (miscellaneous) lock Subscription

Asia-Pacific Journal of Clinical Oncology

Asia-Pacific Journal of Clinical Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 45. It has a price of 2395 €. It has an SJR impact factor of 0,57 and it has a best quartile of Q2. It has an SJR impact factor of 0,57.

ISSN: 1743-7555

Publisher: Wiley-Blackwell Publishing Ltd

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,57 Q2

H-index 45

Acceptance rate pie_chart

35%

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

2.395 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,57

H-index

Docs (year)

110

Docs 3y

395

Total refs

4098

Cites 3y

637

Citable 3y

374

Cites/Doc 2y

1.52

Ref/Doc

37.25

Immediate OA

2395 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Result of extracorporeal irradiation and re-implantation for malignant bone tumors: A review of 30 patients

In this issue

Lymphoid and fibroblastic cell lineages from radiosensitive cancer patients: Molecular analysis of DNA double strand break repair by major non-homologous end-joining sub-pathways

Medium-dose-rate brachytherapy for cancer of the cervix: Preliminary results of a designed schedule

Metastatic gastric cancer: Does the site of metastasis make a difference?

N-acetyltransferase 2 gene polymorphism as a biomarker for susceptibility to bladder cancer in Bangladeshi population

Optimizing the management of advanced breast cancer in the Asia-Pacific region: Role of clinical trials and treatment guidelines

Pemetrexed for malignant pleural mesothelioma: Is it a standard second-line therapy?

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer

Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib

Hypofractionated versus standard fractionation radiotherapy in early glottic cancer: A retrospective review

Sentinel node micrometastases in breast cancer: Clinical outcome

SHOW MORE ARTICLES

Simultaneous comparison of multiple molecules using tissue array analysis in the thyroid neoplasm

Small cell lung cancer presenting with paraneoplastic limbic encephalitis

Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review

The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C

Use of non-anthracycline regimens in early stage breast cancer in Australia

Welcome Message from Conference Co-Convenors

When compared to plasma-based detection, osimertinib-treated non-small cell lung cancer (NSCLC) with tissue rebiopsy-confirmed acquired T790M mutation is associated with better survival

Cholangiocarcinoma in USA- versus Asian-born Asians: Is viral hepatitis a factor?

About the Cancer Research Network

Advanced renal cell carcinoma in Australia, 2015: What should we do?

Aflibercept-related nasal septum perforation

Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: A case series

FAQs

Asia-Pacific Journal of Clinical Oncology has an SJR of 0,57 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is 2395 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Asia-Pacific Journal of Clinical Oncology is 35%.

Asia-Pacific Journal of Clinical Oncology

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Asia-Pacific Journal of Clinical Oncology?

What is the APC / publication cost?

What is the acceptance rate?